当前位置：首页 > 文献互助 > 互助详情

Suzetrigine: First Approval复制

用户1EPy-xGJnvBY 1天前 17 10 已完结

1. 当前求助状态已完结, 请及时下载应助文件

2. 系统将在 2025-06-11 15:35:14 删除文件

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

SJ Keam
Drugs, 2025
Springer
… On 30 January 2025, suzetrigine was approved for the … Suzetrigine is the first NaV inhibitor to be approved in this new … development of suzetrigine leading to this first approval for the …

上一篇： Suzetrigine: The Newest Hammer for Postoperative Pain Whack-a-Mole

下一篇：US Food and Drug Administration Approval of Suzetrigine: A Breakthrough in Nonopioid Pain Management

互助时间线

2025-06-04 17:00:06 [完结求助]

楼主确认了jodie0105应助的文件是正确的, 求助状态变成 已完结

2025-06-04 15:35:14 [上传文件]

jodie0105上传了文件(zip 1011.74 KB), 求助状态变成 待确认

2025-06-04 09:09:14 [发起求助]

最新发布的求助

FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1 8小时前
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 15小时前
Catalytic Hydrogenation of Nitriles over Supported Mono- and Bimetallic Catalysts 16小时前
Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1 17小时前
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5 … 17小时前
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 18小时前
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? 19小时前
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea 19小时前
Устройство для перемещения деталей при обработке их по контуру на швейном полуавтомате 19小时前
Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. 20小时前
Enhanced Charge Transfer Efficiency Using Ring Vertical Transfer Gates in Backside Illuminated CMOS Image Sensor 20小时前
负载型钌催化剂对肉桂醛的液相加氢：粒径、双金属和负载物性质的影响 20小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com